An Epic records analysis presented at the ophthalmology academy meeting found the drop only after adjusting for other conditions. Unadjusted data had pointed to 68% higher odds.
Recap by typeshit. Full story at Medical Daily.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Nearly 250 NAION cases sit in Pennsylvania federal court with hundreds more in New Jersey. Relkin, co-lead counsel, points to a baseline eye exam before starting a GLP-1.
A short post explains what people online mean by GLP-1 microdosing, taking doses below the approved levels, and notes none of it is FDA-sanctioned.
Loading…